Literature DB >> 9152122

Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation.

O Almkvist1, H Basun, S L Wagner, B A Rowe, L O Wahlund, L Lannfelt.   

Abstract

OBJECTIVE: To explore the relationship between possible biological markers of Alzheimer disease that are related to amyloid metabolism and mental functions. PARTICIPANTS: Twelve individuals from a Swedish family with Alzheimer disease and a double mutation at codons 670/671 of the amyloid precursor protein gene participated in the study.
DESIGN: Cerebrospinal fluid levels of alpha-secretase cleaved soluble amyloid precursor protein (alpha-sAPP), total sAPP, and amyloid beta-peptide were correlated with data on multiple cognitive functions that covered the whole range of human performance.
SETTING: The Alzheimer's Disease Research Centre, Department of Clinical Neuroscience, Section of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden.
RESULTS: There were highly significant linear correlations between low levels of alpha-sAPP and poor performance on neuropsychological tests that assessed intelligence, verbal and visuospatial functions, memory, and attention. Within the group of nonmutation carriers, significant correlations were also obtained between the levels of alpha-sAPP and cognitive functions. A less striking association was seen between the levels of total sAPP and cognition. No association was found between the levels of amyloid beta-peptide and cognition.
CONCLUSIONS: The strong relationship between alpha-sAPP levels and cognition in both patients with Alzheimer disease and normal-aging persons may imply that alpha-sAPP is involved in basic protective brain processes. Alternatively, less amyloid beta-peptide amounts are produced, leading to diminished plaque formation, when alpha-sAPP is generated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152122     DOI: 10.1001/archneur.1997.00550170111022

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  20 in total

Review 1.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 2.  Role of APP Interactions with Heterotrimeric G Proteins: Physiological Functions and Pathological Consequences.

Authors:  Philip F Copenhaver; Donat Kögel
Journal:  Front Mol Neurosci       Date:  2017-01-31       Impact factor: 5.639

3.  Distinct in vivo roles of secreted APP ectodomain variants APPsα and APPsβ in regulation of spine density, synaptic plasticity, and cognition.

Authors:  Max C Richter; Susann Ludewig; Alex Winschel; Tobias Abel; Charlotte Bold; Leonie R Salzburger; Susanne Klein; Kang Han; Sascha W Weyer; Ann-Kristina Fritz; Bodo Laube; David P Wolfer; Christian J Buchholz; Martin Korte; Ulrike C Müller
Journal:  EMBO J       Date:  2018-04-16       Impact factor: 11.598

Review 4.  Restoring Soluble Amyloid Precursor Protein α Functions as a Potential Treatment for Alzheimer's Disease.

Authors:  Ahsan Habib; Darrell Sawmiller; Jun Tan
Journal:  J Neurosci Res       Date:  2016-08-17       Impact factor: 4.164

5.  Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.

Authors:  Magdalena Nutu; Philippe Bourgeois; Henrik Zetterberg; Erik Portelius; Ulf Andreasson; Stéphane Parent; Francesco Lipari; Sara Hall; Radu Constantinescu; Oskar Hansson; Kaj Blennow
Journal:  Neuromolecular Med       Date:  2012-12-07       Impact factor: 3.843

Review 6.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

7.  Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice.

Authors:  Brian Giunta; Houyan Hou; Yuyan Zhu; Jon Salemi; Amanda Ruscin; R Douglas Shytle; Jun Tan
Journal:  Neurosci Lett       Date:  2010-01-22       Impact factor: 3.046

8.  Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Petra Steinacker; Corinna Hendrich; Anne-Dorte Sperfeld; Sarah Jesse; Stefan Lehnert; Alice Pabst; Christine A F von Arnim; Felix M Mottaghy; Ingo Uttner; Hayrettin Tumani; Albert Ludolph; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2009-08-01       Impact factor: 3.575

9.  Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid.

Authors:  Qiu-Lan Ma; Douglas R Galasko; John M Ringman; Harry V Vinters; Steven D Edland; Justine Pomakian; Oliver J Ubeda; Emily R Rosario; Bruce Teter; Sally A Frautschy; Greg M Cole
Journal:  Arch Neurol       Date:  2009-04

Review 10.  The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes.

Authors:  Hoang S Nhan; Karen Chiang; Edward H Koo
Journal:  Acta Neuropathol       Date:  2014-10-07       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.